Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
130 hedge funds and large institutions have $243M invested in Jounce Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 65 increasing their positions, 24 reducing their positions, and 14 closing their positions.
171% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 24
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
43% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 14
5% more funds holding
Funds holding: 124 → 130 (+6)
36% less capital invested
Capital invested by funds: $378M → $243M (-$135M)
80% less call options, than puts
Call options by funds: $340K | Put options by funds: $1.73M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$5.67M |
| 2 |
BlackRock
New York
|
+$5.13M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$2.8M |
| 4 |
O
OrbiMed
New York
|
+$2.69M |
| 5 |
Millennium Management
New York
|
+$2.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP II
Boston,
Massachusetts
|
-$17.1M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$15.4M |
| 3 |
CCM
CAAS Capital Management
New York
|
-$10.8M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$5.7M |
| 5 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$5.35M |
JNCE Hedge Fund Activity: Q2 2021 in Review
130 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q2 2021, worth a combined $243M — down 36% from $378M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new JNCE positions and 14 closed out — a net gain of 6 holders — while 65 added to existing stakes and 24 trimmed.
The largest buyer was Assenagon Asset Management, opening a new position worth an estimated $5.67M. The largest seller was TRV GP II, cutting an estimated $17.1M.
- 130 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q2 2021, up from 124 in Q1 2021.
- Funds reported $243M of Jounce Therapeutics, Inc. Common Stock stock for Q2 2021, down 36% quarter-over-quarter.
- 20 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q2 2021 and 14 closed out, a net change of +6 holders.
- The largest Jounce Therapeutics, Inc. Common Stock buyer in Q2 2021 was Assenagon Asset Management, an estimated $5.67M added.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q2 2021 was TRV GP II, an estimated $17.1M sold.
Based on aggregated 13F filings for Q2 2021.